Anal squamous cell carcinoma
disease diseaseOn this page
Also known as anal squamous cell cancerANSCanus squamous cell carcinomaepidermoid anal carcinomaepidermoid carcinoma of anusepidermoid carcinoma of the anussquamous cell anal carcinomasquamous cell carcinoma - anussquamous cell carcinoma of anussquamous cell carcinoma of the anus
Summary
Anal squamous cell carcinoma (MONDO:0006082) is a cancer and 32 clinical trials. Top therapeutic interventions include carboplatin, fludeoxyglucose f 18, and niraparib. A subtype of anal carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 32
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anal squamous cell carcinoma |
| Mondo ID | MONDO:0006082 |
| EFO | EFO:1000081 |
| DOID | DOID:5525 |
| NCIT | C9161 |
| UMLS | C1412036 |
| MedGen | 237257 |
| GARD | 0024286 |
| Anatomy (UBERON) | UBERON:0001245 |
| Is cancer (heuristic) | yes |
Also known as: anal squamous cell cancer · anal squamous cell carcinoma · ANSC · anus squamous cell carcinoma · epidermoid anal carcinoma · epidermoid carcinoma of anus · epidermoid carcinoma of the anus · squamous cell anal carcinoma · squamous cell carcinoma - anus · squamous cell carcinoma of anus · squamous cell carcinoma of the anus
Data availability: 13 cell lines · 14 intOGen driver records.
Disease family
This is a subtype of anal carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › rectal neoplasm › anus neoplasm › anus cancer › anal carcinoma › anal squamous cell carcinoma
Related subtypes (3): anus adenocarcinoma, anal margin carcinoma, anal canal carcinoma
Subtypes (4): anal margin squamous cell carcinoma, anus basaloid carcinoma, anal verrucous carcinoma, anal canal squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 14 |
| Not specified | 9 |
| PHASE1 | 5 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04444921 | PHASE3 | ACTIVE_NOT_RECRUITING | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients |
| NCT05374252 | PHASE3 | UNKNOWN | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients |
| NCT04719988 | PHASE2 | ACTIVE_NOT_RECRUITING | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
| NCT04894370 | PHASE2 | RECRUITING | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma |
| NCT04929028 | PHASE2 | ACTIVE_NOT_RECRUITING | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer |
| NCT06050707 | PHASE2 | RECRUITING | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach |
| NCT07425054 | PHASE2 | NOT_YET_RECRUITING | HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer |
| NCT07555678 | PHASE2 | RECRUITING | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase |
| NCT07602842 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Study of IDP-001 in Advanced or Metastatic Solid Tumors |
| NCT01285778 | PHASE2 | COMPLETED | Vectibix for the Treatment of Anal Cancer |
| NCT01807546 | PHASE2 | COMPLETED | Oral Rigosertib for Squamous Cell Carcinoma |
| NCT02051868 | PHASE2 | UNKNOWN | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel |
| NCT02437851 | PHASE2 | COMPLETED | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection |
| NCT02560298 | PHASE2 | UNKNOWN | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer |
| NCT03221400 | PHASE1/PHASE2 | UNKNOWN | PEN-866 in Patients With Advanced Solid Malignancies |
| NCT03944252 | PHASE2 | UNKNOWN | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) |
| NCT05060471 | PHASE2 | COMPLETED | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients |
| NCT05582031 | PHASE2 | WITHDRAWN | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers |
| NCT07217171 | PHASE1 | RECRUITING | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas |
| NCT01115790 | PHASE1 | COMPLETED | A Phase 1 Study in Participants With Advanced Cancer |
| NCT03517488 | PHASE1 | COMPLETED | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
| NCT03894618 | PHASE1 | COMPLETED | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas |
| NCT04596033 | PHASE1 | TERMINATED | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy |
| NCT05328765 | Not specified | RECRUITING | A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection |
| NCT05438836 | Not specified | RECRUITING | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer |
| NCT05838391 | Not specified | RECRUITING | Adaptive Radiation in Anal Cancer |
| NCT06236464 | Not specified | RECRUITING | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas |
| NCT06697964 | Not specified | RECRUITING | High Resolution Anuscopy Study |
| NCT02162641 | Not specified | WITHDRAWN | Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer |
| NCT02407561 | Not specified | TERMINATED | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays |
| NCT05130073 | Not specified | COMPLETED | 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer |
| NCT07085845 | Not specified | COMPLETED | The Self-Sampling Pilot Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 3 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| NIRAPARIB | 4 | 1 |
| RETIFANLIMAB | 4 | 1 |
| RIGOSERTIB | 3 | 2 |
| PREXASERTIB | 2 | 1 |
| VUDALIMAB | 2 | 1 |
| PEN-866 | 1 | 1 |
| FOLINIC ACID | 0 | 1 |